GetTopicDetailResponse(id=8804966e125, topicName=銷售授權(quán)申請(qǐng), introduction=銷售授權(quán)申請(qǐng), content=null, image=null, comments=4, allHits=712, url=https://h5.medsci.cn/topic?id=96671, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=99375, tagList=[TagDto(tagId=99375, tagName=銷售授權(quán)申請(qǐng))], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1815048, encodeId=7e7f1815048e6, content=<a href='/topic/show?id=8804966e125' target=_blank style='color:#2F92EE;'>#銷售授權(quán)申請(qǐng)#</a>, objectTitle=EMA接受Astellas / Seagen的enfortumab vedotin的銷售授權(quán)申請(qǐng)（MAA）, objectType=article, longId=209073, objectId=c97e2090e362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c97e2090e362, replyNumber=0, likeNumber=74, createdTime=2022-02-08, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c97e2090e362, moduleTitle=EMA接受Astellas / Seagen的enfortumab vedotin的銷售授權(quán)申請(qǐng)（MAA）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c97e2090e362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815049, encodeId=0c3418150495b, content=<a href='/topic/show?id=8804966e125' target=_blank style='color:#2F92EE;'>#銷售授權(quán)申請(qǐng)#</a>, objectTitle=歐洲藥品管理局接受Enfortumab Vedotin的銷售授權(quán)申請(qǐng)（MAA）, objectType=article, longId=209110, objectId=46be20911056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46be20911056, replyNumber=0, likeNumber=114, createdTime=2021-12-23, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46be20911056, moduleTitle=歐洲藥品管理局接受Enfortumab Vedotin的銷售授權(quán)申請(qǐng)（MAA）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=46be20911056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815047, encodeId=3db4181504e35, content=<a href='/topic/show?id=8804966e125' target=_blank style='color:#2F92EE;'>#銷售授權(quán)申請(qǐng)#</a>, objectTitle=EMA接受抗部分性癲癇發(fā)作藥物cenobamate的銷售授權(quán)申請(qǐng), objectType=article, longId=191490, objectId=c3f6191490db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f6191490db, replyNumber=0, likeNumber=94, createdTime=2020-05-31, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f6191490db, moduleTitle=EMA接受抗部分性癲癇發(fā)作藥物cenobamate的銷售授權(quán)申請(qǐng), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c3f6191490db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815046, encodeId=50c9181504695, content=<a href='/topic/show?id=8804966e125' target=_blank style='color:#2F92EE;'>#銷售授權(quán)申請(qǐng)#</a>, objectTitle=歐洲藥品管理局接受GSK靶向BCMA的抗體偶聯(lián)藥物belantamab mafodotin的銷售授權(quán)申請(qǐng), objectType=article, longId=187393, objectId=e5f218e3936c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5f218e3936c, replyNumber=0, likeNumber=97, createdTime=2020-06-06, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5f218e3936c, moduleTitle=歐洲藥品管理局接受GSK靶向BCMA的抗體偶聯(lián)藥物belantamab mafodotin的銷售授權(quán)申請(qǐng), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e5f218e3936c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
